Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
Profound Medical Q1 Earnings Call Highlights
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical Reports Strong First Quarter 2026 Financial Results
Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROF
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. Investigated by the Portnoy Law Firm
Contrasting Profound Medical (NASDAQ:PROF) and Cosmos Health (NASDAQ:COSM)
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates
Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline
Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical Corp. Announces Closing of Private Placement
Profound Medical Corp. Announces Upsize of Private Placement
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Wall Street Analysts Think Profound Medical (PROF) Could Surge 82.37%: Read This Before Placing a Bet
Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Profound Medical (PROF) Just Flashed Golden Cross Signal: Do You Buy?
Profound Medical (PROF) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe Profound Medical (PROF) Could Rally 97.59%: Here's is How to Trade
Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease
Profound Medical Corp. (PRN:CA) Q3 2025 Earnings Call Transcript
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical Reports Strong Third Quarter 2025 Financial Results
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment
Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference
Profound Medical: Smokes Is Everywhere, Initiate At Sell
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical Announces Second Quarter 2025 Financial Results
Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow
Profound Medical (NASDAQ:PROF) Shares Up 17.4% – What’s Next?